Kintor PharmaceuticalKNTPF 20 Median PS Value is $0.00 as of Jun. 29, 2026. GuruFocus rates KNTPF with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 277 Biotechnology companies, Kintor Pharmaceutical ranks worse than 361010.47% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Kintor Pharmaceutical's Median PS Value or its related term are showing as below:
KNTPF's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.62 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Kintor Pharmaceutical (OTCPK:KNTPF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Kintor Pharmaceutical's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.342
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintor Pharmaceutical Median PS Value Related Terms
Kintor Pharmaceutical Median PS Value Historical Data
* Premium members only.
The historical data trend for Kintor Pharmaceutical's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNTPF vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Kintor Pharmaceutical's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kintor Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintor Pharmaceutical (KNTPF) has a Median PS Value of $0.00 as of Jun. 29, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Kintor Pharmaceutical and its competitors. According to the industry distribution chart, Kintor Pharmaceutical ranks #999999 out of 277 companies in the Biotechnology industry.
Is Kintor Pharmaceutical's Median PS Value too high?
Kintor Pharmaceutical's current Median PS Value is $0.00. Based on the distribution chart, Kintor Pharmaceutical ranks #999999 out of 277 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kintor Pharmaceutical has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #999999 out of 277 companies for Median PS Value. This places Kintor Pharmaceutical in the lower half of its industry. The industry median Median PS Value is 0.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Kintor Pharmaceutical and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kintor Pharmaceutical's current Median PS Value is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current Median PS Value of $0.00. The current Median PS Value is $0.00. Kintor Pharmaceutical's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current Median PS Value is $0.00 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
20GF Score
Get the complete analysis for KNTPF
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNTPF has been successfully added to your 
